Japanese drugmaker Takeda Pharmaceuticals Co. on Wednesday said it would maintain its pricing model in the U.S., despite President Trump's demands to lower drug costs in the country, reports Reuters.
The drugmaker, which develops cancer treatments, earns about a third of its drug revenue from the U.S., representing its biggest market outside of Japan, according to the report.
"Takeda has for many years been reasonable in its price increases in the U.S. and we are very committed to single-digit price increase," Takeda CEO Christophe Weber told reporters Wednesday.
The company acquired Ariad Pharmaceuticals for $5.2 billion in January and said it was looking for more acquisitions to expand its drug portfolio and move to more overseas markets, according to the report.
More articles on suply chain:
Shifting drug production back to US could raise prices: 5 takeaways
Mayo Clinic physician: A stripped down FDA would be 'chaotic'
Bard Peripheral Vascular recalls Halo One guiding sheath